A brain cancer diagnosis can be devastating to patients and their families. The statistics below are a powerful reminder of why Tocagen is seeking to provide meaningful increases in survival.
- Gliomas include all tumors arising from the supportive tissue of the brain, and account for about 80 percent of all malignant brain tumors.
- About 14,000 new cases of high-grade gliomas, or HGG, are expected to be diagnosed in the United States in 2017. HGG tumors include glioblastoma, or GBM, and anaplastic astrocytoma, or AA.
- GBM accounts for about half of all primary brain and central nervous system (CNS) cancers.
- The one-, five- and ten-year survival rates for patients with GBM is 37.2 percent, 5.1 percent, and 2.6 percent from diagnosis respectively, making it one of the most lethal among all cancers.
Source: Ostrom et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology 17:iv1 –iv62, 2015.
Tocagen is developing a product candidate to treat HGG, which is under evaluation in a Phase 3 clinical trial, Toca 5. Learn about the Toca 5 trial.
See additional brain cancer resources below: